EQUINOX NEPREMICNINE d.d (EQNX) Stock Overview
Engages in the rental and operation of real estate properties in Slovenia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
EQNX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
EQUINOX NEPREMICNINE d.d. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €61.00 |
| 52 Week High | €61.00 |
| 52 Week Low | €54.00 |
| Beta | -0.049 |
| 1 Month Change | 3.39% |
| 3 Month Change | 7.96% |
| 1 Year Change | 7.96% |
| 3 Year Change | 27.62% |
| 5 Year Change | n/a |
| Change since IPO | 64.86% |
Recent News & Updates
Shareholder Returns
| EQNX | SI Real Estate | SI Market | |
|---|---|---|---|
| 7D | 0% | -0.6% | 0.9% |
| 1Y | 8.0% | 3.3% | 38.0% |
Return vs Industry: EQNX exceeded the SI Real Estate industry which returned 3.3% over the past year.
Return vs Market: EQNX underperformed the SI Market which returned 38% over the past year.
Price Volatility
| EQNX volatility | |
|---|---|
| EQNX Average Weekly Movement | 2.7% |
| Real Estate Industry Average Movement | 4.5% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in SI Market | 5.3% |
| 10% least volatile stocks in SI Market | 3.0% |
Stable Share Price: EQNX has not had significant price volatility in the past 3 months compared to the SI market.
Volatility Over Time: EQNX's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | n/a | n/a | equinox.si |
EQUINOX NEPREMICNINE d.d. engages in the rental and operation of real estate properties in Slovenia. Its properties include hotels, offices, and apartments. The company was founded in 2021 and is headquartered in Ljubljana, Slovenia.
EQUINOX NEPREMICNINE d.d. Fundamentals Summary
| EQNX fundamental statistics | |
|---|---|
| Market cap | €108.98m |
| Earnings (TTM) | €1.43m |
| Revenue (TTM) | €9.29m |
Is EQNX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EQNX income statement (TTM) | |
|---|---|
| Revenue | €9.29m |
| Cost of Revenue | €2.13m |
| Gross Profit | €7.15m |
| Other Expenses | €5.72m |
| Earnings | €1.43m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.80 |
| Gross Margin | 77.01% |
| Net Profit Margin | 15.45% |
| Debt/Equity Ratio | 20.7% |
How did EQNX perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/07 14:49 |
| End of Day Share Price | 2025/07/01 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
EQUINOX NEPREMICNINE d.d. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mihael Antolic | InterCapital Securities Ltd. |